CEO JLLC NATIVITA Republic of Belarus and CIM S.A. (CENTRO DE INMUNOLOGIA MOLECULAR) Republic of Cuba with the support of the Embassy of the Republic of Belarus in the Republic of Cuba and participation of BioCubaFarma entered into a treaty on the transfer technology of full cycle production and quality control of the vaccine CIMAvax-EGF.
The medical department of NatiVita has prepared a scientific review “How to optimize trastuzumab adjuvant treatment of early-stage HER2-positive breast cancer”, which was published in the leading Belarusian professional publication in the field of oncology “Oncological Journal” (Oncological Journal 2020; 14(2-3): 131-140).